[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"granulocyte-colony-stimulating-factor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:granulocyte-colony-stimulating-factor":104},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100570786","effect-of-g-csf-on-mdsc-and-cancer-stem-cells-interactions-in-non-small-cell-lung-cancers-circuit-100570786",false,"NCT06711770","Effect of G-CSF on MDSC and Cancer Stem-cells Interactions in Non-small Cell Lung Cancers (CIRCUIT)","Characterization of the Effect of G-CSF on the Interactions Between MDSC and Cancer Stem-cells in Non-small Cell Lung Cancers (CIRCUIT)","CIRCUIT","Inclusion Criteria:\n\n* Patients (male or female) aged ≥ 18 years\n* Histological or cytological proven lung adenocarcinoma, metastatic or locally advanced not accessible to local therapy\n* Receiving chemotherapy and immunotherapy as first-line treatment\n* Signed written informed consent (no later than the day of inclusion, and before the blood sample collection)\n* Patient affiliated or beneficiary to a health security system;\n\nExclusion Criteria:\n\n* Patient with a small cell lung carcinoma\n* Non-metastatic disease\n* Actionable mutation or genomic alteration in EGFR, ALK or ROS1\n* Corticosteroids \\> 10 mg\u002Fj\n* Autoimmune disease\n* Active and uncontrolled HIV infection\n* Concomitant cancer\n* Pregnancy or lactating women\n* Psychiatric or medical conditions that prohibit the understanding and rendering of informed consent\n* Patient under a legal protection measure\n* Patient with a deprived liberty condition\n* Patient incapable of giving signed informed consent\n* Patient within the exclusion period for another clinical trial, or participating to another interventional trial within 30 days before the beginning of this project","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","Immunotherapy have revolutionized the field of oncology, but response rates are low and all patients relapse, due to immunologic (myeloid immunosuppressive cells) and non-immunologic (cancer stem- cells (CSC)) mechanisms. CSC are able to circulate within blood, protected from destruction by immunosuppressive cells such as MDSC. Some factors such as G-CSF, administered to lower febrile neutropenia, should modulate properties of MDSC and CSC, but data are contradictory, and literature remain poor regarding its effects on the interactions between MDSC and CSC in blood clusters. Indeed, this project aims at better characterizing the effect of G-CSF on these interactions and on their functions in NSCLC patients receiving G-CSF.",[27,28,29],"Non Small Cell Lung Cancer","Immunotherapy","Granulocyte Colony Stimulating Factor",[31,28,32,33],"Non-small cell lung cancer","Myeloid-Derived Suppressor Cells","Granulocyte-Colony Stimulating Factor","NOT_YET_RECRUITING","2025-07-29",{"date":37,"type":38},"2025-07-30","ACTUAL",{"date":40,"type":21},"2025-12",{"date":42,"type":21},"2028-12",{"name":44,"class":45},"University Hospital, Bordeaux","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":5},"100567249","phase-4-outcomes-of-early-and-late-administration-g-csf-for-primary-prophylaxis-in-non-hodgkins-lymphoma-patients-100567249","NCT06665737","Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients","A Comparison Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients Who Receive Chemotherapy, Multicenter Study","G-CSF in NHL","Inclusion Criteria:\n\n* Aged 18 years or old\n* Confirmed lymphoma undergoing standard chemotherapy\n* Signed an approval informed consent\n* Has a good understanding of Thai\n* Available for follow-up after chemotherapy\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Serious concomitant diseases and discontinuous treatment such as cardiovascular, liver, or kidney diseases\n* Contraindication to chemotherapy or G-CSF administration\n* Antibiotic use within 1 week prior to enrollment",{"count":56,"type":21},126,[58],"PHASE4","The goal of this clinical trial is to\n\nPrimary Objectives:\n\n1. To compare the incidence of febrile neutropenia in patients with non-Hodgkin's lymphoma who received early or late granulocyte colony-stimulating factor (G-CSF) during standard chemotherapy in a multicenter study\n2. To determine the incidence of leukopenia and neutropenia in patients with non-Hodgkin's lymphoma who received early or late G-CSF during standard chemotherapy in a multicenter study\n\nSecondary Objectives:\n\n1. To determine changes in white blood cell, hemoglobin, and platelet levels in patients with non-Hodgkin's lymphoma who received early or late G-CSF during standard chemotherapy.\n2. To determine the quality of life of patients with non-Hodgkin's lymphoma who undergoing standard chemotherapy and with neutropenia Researchers will compare the outcome between patients received either early G-CSF (within 72 hours) or late G-CSF (after 72 hours).\n\nAll patients will be followed up to monitor for febrile neutropenia events, other hematological parameters and quality of life.",[61,29,62,63],"Non-Hodgkin's Lymphoma (NHL)","Febrile Neutropenia (FN)","Myelosuppression Adult",[65,66,29,67],"Non-Hodgkin's lymphoma","Febrile neutropenia","Myelosuppression","2025-01-24",{"date":70,"type":38},"2025-01-28",{"date":72,"type":21},"2025-02-01",{"date":74,"type":21},"2026-12-31",{"name":76,"class":77},"Department of Medical Services Ministry of Public Health of Thailand","OTHER_GOV",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":17,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":46},"100570540","evaluation-of-the-use-of-granulocyte-colony-stimulating-factor-gcsf-in-post-kasai-type-3-biliary-atresia-100570540","NCT06708572","Evaluation of the Use of Granulocyte Colony Stimulating Factor (GCSF) in Post Kasai Type 3 Biliary Atresia","Inclusion Criteria:\n\n* Infants with initial diagnosis of biliary atresia with biliary atresia score \\> 23.927 will be allocated for Kasai porto-enterostomy with intra-operative cholangiogram reaching type 3 biliary atresia anatomy as a final diagnosis.\n\nExclusion Criteria:\n\n* Major cardiac, renal, pulmonary, neurological malformations or illnesses.\n* Hemoglobinopathies, such as sickle cell anemia\n* Active systemic infection.\n* White blood cell count \\> 20,000 cells\u002Fmm3.\n* Platelet count \\\u003C 40,000 cells\u002Fmm3 or ≥ 800,000 cells\u002Fmm3.\n* Purpura fulminans or unexplained vascular thrombotic conditions.",true,"20 Days","1 Year",{"count":88,"type":21},40,[24],"The aim of the study is to evaluate the use of Granulocyte Colony Stimulating Factor (GCSF) on the clinical and biochemical outcome of type 3 biliary atresia post kasai.",[92,93],"Granulocyte Colony-stimulating Factor","Biliary Atresia","RECRUITING","2024-12-09",{"date":97,"type":38},"2024-12-11",{"date":99,"type":21},"2024-12",{"date":101,"type":21},"2026-10-30",{"name":103,"class":45},"National Liver Institute, Egypt","Granulocyte Colony-Stimulating Factor"]